Field 4 – New Therapeutic solutions
will provide access to a wide range of state-of-the-art services aiming to facilitate the development of novel therapeutic solutions for innovative personalised cancer research, as well as facilitate both clinical and translational research studies with focus mainly on: a) incorporate Small Molecules and Screening and b) Advanced Therapies and Biologicals Development Services.
| Unique ID | Country | Service Name | Description of Service | Research Infrastructure | Service Provider | Unit of access | Website |
|---|---|---|---|---|---|---|---|
| 4.7_BIOGEM-Scarl / AMCF | IT | Xenograft in zebrafish embryos for drug testing | Xenograft in zebrafish embyos with fluoreecently-labelled cells , also patient derived. The service includes: cell growth and staining, cell injection, waterbone drug testing , imaging , within 3 days post-injection, and data analysis | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Animal Model Core Facility | 1 experimental group of 20 larvae injected with fluoreecently-labelled cells , also patient derived. | https://biogem.it/index.php/en/ |
| 4.8_BIOGEM scarl/AMCF A. | IT | Innate immunity cell cancer interaction analyses | Genetically modified embryos having fluorescent innate immune cells will be used for xenograft embryo assay. The service includes: cell growth and staining, cell injection in zebrafish embryos drug exposure ( waterbone, yolk or intravenous injecrion), imaging , within 3 days post-injection, and data analysis. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Animal Model Core Facility | 1 experimental group of 20 larvae, from transgenic lines carrying fluorescently labelled innate immune cells, injected with fluoreecently-labelled cells , also patient derived | https://biogem.it/index.php/en/ |
| 4.9_AMCF | IT | Waterborne drug testing | The service include drug preparation, changes of the fish water up to the drug half-life, evaluation of embryos vitality and development. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Animal Model Core Facility | 1 experimental group of 20 larvae exposed in fish water | https://biogem.it/index.php/en/ |
| 4.10_AMCF | IT | Drug testing in adult | The service includes drug preparation, changes of the fish water up to the drug half-life, evaluation of embryos vitality and development. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Animal Model Core Facility | 1 access unit is a vask containing 10 males and 10 females | https://biogem.it/index.php/en/ |
| 4.11_BIOGEM scarl /AMCF | IT | Drug testing by yolk or intravenous injection | The service includes: drug preparation, animal anestesia, animal injection and monitoring. | BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) | Animal Model Core Facility | 1 larva or 1 adult zebrafish injected | https://biogem.it/index.php/en/ |
| 4.12_Alonso MJ Lab_IDIS | ES | Design, production and validation of advanced nanotech-ATMP therapies | Design, production and validation of advanced therapies (ATMP) based on nanotechnologies for the delivery of proteins and RNA sequences to therapeutically manipulate the immune system | EATRIS ERIC (EATRIS) | Health Research Institute of Santiago de Compostela (IDIS) | Library of minimum 20 nanoformulations and … | https://www.idisantiago.es/ |
| 4.13_ Microfluidics Models_ISS | IT | Microfluidic device experiments and analysis | Fluidic or microfluidic devices for immune response and cell therapy testing | EATRIS ERIC (EATRIS) | Istituto Superiore di Sanità (ISS) | 1 run/experiment | https://www.iss.it/ |
| 4.14_Flow cyto.Unit_CHUC | PT | Identification and quantification of the tumour immune infiltrate by flow cytometry | Identification and quatification of the tumour immune infiltrate by flow cytometry, including Th1, Th2, Th17 and Treg cells, and their plasticity, cytotoxic T cells, γδ T cells, and double negative αβ T cells, M1 and M2 macrophages. Study of the expression of immunosuppressive molecules and/or their receptors by tumour cells, immune cells infiltrating the tumour, and their peripheral blood counterparts, including PD-1/PD-L1, IDO, CD39/CD73/A2A adenosine receptor (ADORA2A), CD200/CD200R, and TIM-3. | EATRIS ERIC (EATRIS) | Centro Hospitalar e Universitário de Coimbra (CHUC) | sample | https://www.chuc.min-saude.pt/ |
| 4.15_in-vivo models_IRCCS | IT | Pre-clinical assessment of ATMPs in tumor cell models | Preclinical assessment of efficacy and specificity of advanced therapies in clinical relevant neuroblastoma models, such as orthotopic (well-established tumor in the adrenal gland), metastatic (circulating tumor cells and metastases), resected (surgical resection of the primary tumor mass for minimal residual disease), and PDX (Patient-Derived Xenografts) models. | EATRIS ERIC (EATRIS) | IRCCS ISTITUTO GIANNINA GASLINI (IGG) | disease model | https://www.gaslini.org/ |
| 4.16_Osteoncology_IRST | IT | Synthesis and characterization of Nanoparticles | Synthesis and characterization of Nanoparticles | EATRIS ERIC (EATRIS) | Istituto Tumori della Romagna IRST IRCCS | Synthesis of 1 nanoparticle type (5-20 mg/ml) | https://www.irst.emr.it/it/ |
| 4.17_Radiobiomics&Drug | IT | Study of ATMP efficacy | Study of ATMP efficacy | EATRIS ERIC (EATRIS) | Istituto Tumori della Romagna IRST IRCCS | Drug analysis | https://www.irst.emr.it/it/ |
| 4.18_Quintarelli LAb.OPBG | IT | Allogenic NK CAR | Development and characterization of Allogenic CAR NK cells from peripheral blood of healthy donors | EATRIS ERIC (EATRIS) | Ospedale Pediatrico Bambino Gesù - OPBG | Study (preclinical) | https://www.ospedalebambinogesu.it/ |
| 4.19_Quintarelli Lab_OPBG | IT | Gene editing for complex CART cell engineering | Development and characterization of CAR T cells optimed by the the gene editing of key elements regulating efficacy and persistence | EATRIS ERIC (EATRIS) | Ospedale Pediatrico Bambino Gesù - OPBG | Study (preclinical) | https://www.ospedalebambinogesu.it/ |
| 4.20_Inderberg_UOH | NO | Generation of CAR-T Cells | Batches of frozen CAR-T cells can be generated from healthy donor T cells through retroviral transduction or mRNA transfection and frozen down in aliquots. | EATRIS ERIC (EATRIS) | Oslo Unversity Hospital (UOH) | Sample-RV transduction | https://oslo-universitetssykehus.no/oslo-university-hospital |
| 4.21_Inderberg_UOH | NO | Pre-clinical Assessment of CAR-T metabolism | Pre-clinical Assement of CAR-T Efficacy (Determination of the metabolic consumption of the CAR expressing cell ) | EATRIS ERIC (EATRIS) | Oslo Unversity Hospital (UOH) | Run (plate)- Seahorse (metabolism) | https://oslo-universitetssykehus.no/oslo-university-hospital |
| 4.22_Inderberg_UOH | NO | Live-cell imaging based CAR-T killing assays | Evaluation of CAR-T, CAR-NK, CAR-NKT cell target killing efficacy (IncuCyte live-cell imaging of tumour cell spheroids or 2D cultures ) using probes for measuring apoptosis. | EATRIS ERIC (EATRIS) | Oslo Unversity Hospital (UOH) | Run (plate)- IncuCyte | https://oslo-universitetssykehus.no/oslo-university-hospital |
| 4.23_Inderberg_UOH | NO | Bio-Plex: multiplex cytokine measurement | Evaluation of CAR-T, CAR-NK, CAR-NKT cytokine production, high-throughput multiplex immunoassay: Bio-Plex multiplex cytokine for measurement of cytokine levels in culture supernatant or serum/plasma samples. | EATRIS ERIC (EATRIS) | Oslo Unversity Hospital (UOH) | Run (plate)- BioPlex | https://oslo-universitetssykehus.no/oslo-university-hospital |
| 4.24_Inderberg_UOH | NO | Characterization of CAR-T, CAR-NK, CAR-NKT cell phenotype | Phenotyping of immune cells by mass cytometry (CyTOF), extracellular markers with around 35 marker panel including lineage markers, activation markers, exhaustion markers, memory markers. Intracellular staining can be performed, but will require validation. | EATRIS ERIC (EATRIS) | Oslo Unversity Hospital (UOH) | Run (hours)- CyTOF (Helios) | https://oslo-universitetssykehus.no/oslo-university-hospital |
| 4.25_Rodents&Zebrafish_iMM | PT | Animal Models for In vivo Validation of ATMPs | Relevant cancer animal models for in vivo validation of ATMPs. Examples include acute myeloid leukemia (AML) induction, orthotropic colon cancer induction, cerebral metastases, subcutaneous cancer / tumor induction, mammary fat pad tumor induction, B16 melanoma model, different models for breast and pancreatic cancers. | EATRIS ERIC (EATRIS) | Instituto de Medicina Molecular João Lobo Antunes (iMM) | Animal models | https://imm.medicina.ulisboa.pt/ |
| 4.26_CPU_iMM | PT | In vivo validation of ATMPs design and planning | Histopathology for In vivo Validation of ATMPs: Pathology consultation - design and planning of animal studies; guidance in necropsy procedures; selection of fit-for-purpose histological and histochemical methods | EATRIS ERIC (EATRIS) | Instituto de Medicina Molecular João Lobo Antunes (iMM) | Histopath. for InVivo Valid. of ATMPs:path.consult | https://imm.medicina.ulisboa.pt/ |
| 4.27_CPU_iMM | PT | In vivo validation of ATMPs tumor volume | Histopathology for In vivo Validation of ATMPs: Histopathological analysis - efficacy evaluation by tumour volume including reporting | EATRIS ERIC (EATRIS) | Instituto de Medicina Molecular João Lobo Antunes (iMM) | Histopath. analysis-efficacy evalu. by tumour vol | https://imm.medicina.ulisboa.pt/ |
| 4.28_CPU_iMM | NO | In vivo validation of ATMPs bioluminiscence | Histopathology for In vivo Validation of ATMPs: Histopathological analysis - efficacy evaluation by bioluminescence imaging including reporting and capture of quality images | EATRIS ERIC (EATRIS) | Instituto de Medicina Molecular João Lobo Antunes (iMM) | Histopath. analysis-efficacy eval. by biolum. imag | https://imm.medicina.ulisboa.pt/ |
| 4.1_UiO-NCMM | NO | Biochemical high-throughput screening (100.000 compounds) | High-throughput screening in BSL1 facility. The assay needs to be HTS-compatible with demonstrated performance in 384-well format. The service includes assay transfer, HTS and hit validation. Service only available in combination with the in-house ECBL (European Chemical Biology Library). | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | University of Oslo | 3-months project (HTS screen) | https://www.med.uio.no/ncmm/english/ |
| 4.2a_UH- FIMM | FI | Cell-based high-throughput screening (100.000 compounds) | Cell-based screen including phenotypic, and target-based screening in human cells in BSL2 facility. The assay needs to be HTS-compatible with demonstrated performance in 384-well format. The service includes assay transfer, HTS and hit validation. Service only available in combination with the in-house ECBL (European Chemical Biology Library). | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | University of Helsinki | 6-months project (HTS screen) | https://www.helsinki.fi/en/infrastructures/drug-discovery-chemical-biology-and-screening/infrastructures/fimm-high-throughput-biomedicine-unit |
| 4.2b_USC | ES | Cell-based high-throughput screening (100.000 compounds) | Cell-based screen including phenotypic, and target-based screening in human cells in BSL2 facility. The assay needs to be HTS-compatible with demonstrated performance in 384-well format. The service includes assay transfer, HTS and hit validation. Service only available in combination with the in-house ECBL (European Chemical Biology Library). | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | University of Santiago de Compostela | 4-months project (HTS screen) | https://www.usc.gal/en/department/pharmacology-pharmacy-and-pharmaceutical-technology |
| 4.3_CIPF | ES | Phenotypic high-throughput screening on 2D/ 3D cell cultures | Phenotypic Assay: Assessment and development of drug functional assays (including Cell death mechanisms, cell cycle, specific intra or extracellular pathways, inflammasome modulation....) in 2D and 3D cell cultures (spheroids) including also identification of combination drug therapies and combination drug + radiotherapy. Includes Assay development/miniaturasation to 96/364. If either Combination Therapies or Radiotherapy is not needed, the costs will be reduced. Cells from different tumors of different subtypes available (including Breast, prostate, Lung, colon, melanoma, head and neck, liver, ovarian, pancreatic, neuroblastoma). | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | Centro de Investigación Príncipe Felipe | 6-months project (HTS screen) | http://vicentresearchlab.com/ |
| 4.4_CCMF | DE | European Chemical Biology Library (ECBL) composed of approx. 100.000 compounds | Preparation of assay-ready plates with 100,000 small molecules containing 2464 bioactives. The ECBL is only available in combination with a selected site for high-throughput screening. | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | EU-OPENSCREEN ERIC | 100.000 compounds | http://eu-openscreen.eu |
| 4.5a_DTU | DK | Medicinal chemistry support including chemical optimization or probe development | Hit-to-lead medicinal chemistry, including SAR (by catalogue and de novo synthesis) and PD/PK optimization. | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | Technical University of Denmark | 6-months project (med chem) | https://orbit.dtu.dk/en/organisations/department-of-chemistry |
| 4.5b_FVB-FMP | DE | Medicinal chemistry support including chemical optimization or probe development | Hit identification and hit expansion, target deconvolution as well as hit-to-lead and multiparameter optimization towards an advanced pharmacological lead. By applying the principles of medicinal chemistry including strategies such as fragment growing, re-scaffolding or hybridization approaches, structure-based design including secondary parameters such as selectivity and ADME or pharmacokinetic properties, the small molecules ligands are chemically modified. By this, the chemical optimization and development of potent and selective small molecule chemical tools and advanced leads to probe the pharmacological function. | EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM (EU-OPENSCREEN ERIC) | FORSCHUNGSVERBUND BERLIN | 6-months project (med chem) | https://leibniz-fmp.de/ |
More information about individual services, please contact us.